Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2012

View Archived Issues

Novel cytochrome P450 inhibitors patented by German university

Research in Korea yields new HIF1-alpha inhibitors

Ardelyx describes novel phosphate transport inhibitors

Pfizer describes novel antiandrogen for castration-resistant prostate cancer

High-risk prostate carcinoma-related death linked to miR-221 expression

Bionomics commences phase I/II trial of vasculature-disrupting agent in ovarian cancer

Genmab receives Arzerra milestone payment

In vivo results presented for new antibody-drug conjugate

Novel treatments for Parkinson's disease prepared at Merck & Co.

Scientists at Nektar Therapeutics present new polymer-GLP-1 conjugates

Morphotek produces novel monoclonal antibodies for cancer

Merck & Co. describes novel protein kinase inhibitors

Rigel presents preclinical data for new antiasthma drug candidate

Anti-IL10 receptor monoclonal antibody enhances BCG antitumor responses

XenoPort submits IND for potential multiple sclerosis treatment

Second cohort opens enrollment in ATOMIC-AHF trial

Lucigen receives NIH grant for RNA-based diagnostic

Kancera's ROR inhibitors show activity against fludarabine-resistant CLL

Oryzon set to begin preclinical development of hematological cancer drug

Chugai files for approval in Japan of pertuzumab

PharmaGap conditionally approves offer for GAP-107B8 license

IMI launches public-private research program to combat antibiotic resistance

Shionogi obtains additional approvals for carbapenem-type antibiotic in Japan

FDA advisory committee votes on Pfizer's data package for TTR stabilizer

RetroSense Therapeutics obtains guidance for lead biologic for eye diseases

AstraZeneca obtains approval for Inderal for new indication in Japan

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...